Kim A. Connelly

FRACP, PhD, MBBS

Scientist

Biography

Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally recognized as an expert in echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function and ventricular remodeling. His work has been recognized evident by winning the “Young Investigator of the Year Award” by the Canadian Cardiovascular Society, an Early Researcher Award in 2014, and a CIHR New Investigator award in 2014.

Dr. Connelly runs a basic research laboratory at the Keenan Research Centre at St. Michael’s Hospital where he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular matrix accumulation and the pro-sclerotic cytokine transforming growth factor beta, with a focus upon translating discoveries into therapies in humans. He developed the first hemodynamically validated model of diabetes induced HFpEF. He is the Director of the Krembil Stem Cell Facility at St. Michael’s Hospital and uses regenerative cell based therapies to improve cardiac and renal dysfunction as a result of diabetes. He has research support from the HSF of Canada, CIHR and CFI along with significant research support from the pharmaceutical industry. His work has been published in journals such as the NEJM, Circulation, Journal of the American college of Cardiology, Circulation Research, Diabetes, Cell Metabolism and Lancet Endocrinology and Diabetes.

His H index is 45, and I index of 140.

Dr Connelly is immediate past president of the Canadian Society of Cardiac Magnetic resonance imaging. He runs a translational imaging laboratory and uses hyperpolarized C13 metabolic imaging to understand metabolism in the human heart in real time, as well as CMR to understand the impact of exercise upon cardiac remodeling. He was senior author of the EMPA HEART study along with Dr Verma and Zinman to assess the mechanism by which the SGLT2i empagliflozin provided cardiac protection in patients with type 2 DM. Finally, he was past section lead of 2018 macrovascular complications section for the Diabetes Canada Clinical practice updates and is current chair of the Canadian Cardiovascular Society guidelines.

Recent Publications

  1. Vanherle, L, Lidington, D, Uhl, FE, Steiner, S, Vassallo, S, Skoug, C et al.. Restoring myocardial infarction-induced long-term memory impairment by targeting the cystic fibrosis transmembrane regulator. EBioMedicine. 2022;86 :104384. doi: 10.1016/j.ebiom.2022.104384. PubMed PMID:36462404 .
  2. Scotti, A, Coisne, A, Taramasso, M, Granada, JF, Ludwig, S, Rodés-Cabau, J et al.. Sex-Related Characteristics and Short-Term Outcomes of Patients Undergoing Transcatheter Tricuspid Valve Intervention for Tricuspid Regurgitation. Eur Heart J. 2022; :. doi: 10.1093/eurheartj/ehac735. PubMed PMID:36445158 .
  3. Connelly, KA, Mazer, CD, Puar, P, Teoh, H, Wang, CH, Mason, T et al.. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial. Circulation. 2022; :. doi: 10.1161/CIRCULATIONAHA.122.062769. PubMed PMID:36335517 .
  4. Moses, S, Verma, S, Mazer, CD, Teoh, H, Quan, A, Jimenez-Juan, L et al.. Impact of Empagliflozin on Left Ventricular Strain: Insights From the EMPA-HEART CardioLink-6 Randomized Clinical Trial. JACC Cardiovasc Imaging. 2022;15 (10):1832-1834. doi: 10.1016/j.jcmg.2022.05.019. PubMed PMID:36202464 .
  5. Connelly, KA, Wu, E, Visram, A, Friedberg, MK, Batchu, SN, Yerra, VG et al.. The SGLT2i Dapagliflozin Reduces RV Mass Independent of Changes in RV Pressure Induced by Pulmonary Artery Banding. Cardiovasc Drugs Ther. 2022; :. doi: 10.1007/s10557-022-07377-1. PubMed PMID:36173474 .
  6. Ali, MU, Mancini, GBJ, Fitzpatrick-Lewis, D, Lewis, R, Jovkovic, M, Zieroth, S et al.. Reply to Du et al.-Obvious Differences Between GLP1RAs and SGLT2is in the Outcomes of Heart Failure, Renal Failure, and Stroke. Can J Cardiol. 2022; :. doi: 10.1016/j.cjca.2022.09.017. PubMed PMID:36152771 .
  7. Dorian, P, Allan, KS, Connelly, KA. Sport, Myocarditis, and Sudden Death: A Perfect Storm?. Can J Cardiol. 2022;38 (11):1693-1696. doi: 10.1016/j.cjca.2022.09.014. PubMed PMID:36150582 .
  8. Mauro, AN, Turgeon, PJ, Gupta, S, Brand-Arzamendi, K, Chen, H, Malone, JH et al.. Automated in vivo compound screening with zebrafish and the discovery and validation of PD 81,723 as a novel angiogenesis inhibitor. Sci Rep. 2022;12 (1):14537. doi: 10.1038/s41598-022-18230-8. PubMed PMID:36008455 PubMed Central PMC9411172.
  9. Chu, A, Shah, BR, Rashid, M, Booth, GL, Fazli, GS, Tu, K et al.. Trends in glucose testing among individuals without diabetes in Ontario between 2010 and 2017: a population-based cohort study. CMAJ Open. 2022;10 (3):E772-E780. doi: 10.9778/cmajo.20210195. PubMed PMID:35998927 PubMed Central PMC9402266.
  10. Ali, MU, Mancini, GBJ, Fitzpatrick-Lewis, D, Lewis, R, Jovkovic, M, Zieroth, S et al.. The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis. Can J Cardiol. 2022;38 (8):1201-1210. doi: 10.1016/j.cjca.2022.05.011. PubMed PMID:35961756 .
Search PubMed

Affiliations & Other Activities

  • Director, Krembil Stem Cell Facility, St. Michael’s Hospital
  • Staff Cardiologist, Division of Cardiology, St. Michael’s Hospital
  • Member, Richard Lewar Center, University of Toronto
  • Cardiologist, Division of Cardiology, Sunnybrook Health Sciences Centre